Go Pro
NASDAQ:JUNS

Jupiter Neurosciences 12/23/2024 Earnings Report

Jupiter Neurosciences logo
$4.18 -0.71 (-14.52%)
As of 08/28/2026 04:00 PM Eastern

Jupiter Neurosciences EPS Results

Actual EPS
-$1.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Jupiter Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jupiter Neurosciences Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Jupiter Neurosciences' next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules.

Conference Call Resources

Jupiter Neurosciences Earnings Headlines

A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.tc pixel
See More Jupiter Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jupiter Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jupiter Neurosciences and other key companies, straight to your email.

About Jupiter Neurosciences

Jupiter Neurosciences (NASDAQ:JUNS), a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

View Jupiter Neurosciences Profile